Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03204721
Other study ID # 2016/1130
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 21, 2017
Est. completion date April 30, 2021

Study information

Verified date February 2022
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim is to test the preventive use of extracorporeal photophoresis (ECP) against development of graft-versus-host disease (GVHD) in patients undergoing allogeneic stem cell transplantation for hematological malignancy.


Description:

Allogeneic stem cell transplantation represents the only available long-term control and possible cure of a number of hematological malignancies. A major obstacle to this treatment is the development of graft-versus-host disease (GVHD), affecting the majority of transplanted patients to some extent. Today, combinations of various cytotoxic and immunosuppressive drugs are used to prevent and treat GVHD, but many of them are associated with severe side-effects. Extracorporeal photophoresis (ECP) offers an alternative to chemo- and immunosuppressive therapy and confers apparently only mild side effects. The postulated rationale of ECP is to treat the patient's white blood cells ex vivo with ultraviolet irradiation after sensitization with 8-methoxypsoralen to dampen their immunoactivity. After engraftment the intervention group receives 2 consecutive ECP every week in 2 weeks then 1 ECP every week in 4 weeks ( a total of 8 ECP procedures).


Recruitment information / eligibility

Status Completed
Enrollment 158
Est. completion date April 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provide written consent to participate - Understand Norwegian or English - No previous history of malignant disease - No contraindication to ECP-treatment or undergone previous ECP treatment Exclusion Criteria: - (in addition to those regarding eligibility for transplantation itself): - Unwilling to provide written consent to participate - Unable to cooperate as judged by the responsible physician - ECOG status > 2 at time of inclusion - Using anti-inflammatory or cytotoxic drugs other than those that are part of the treatment of the current hematological malignancy - Known allergy to psoralens or citrate products - Splenectomy - Pregnancy/lactating

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Extracorporeal photophoresis (ECP)
The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient

Locations

Country Name City State
Norway Tobias Gedde-Dhl Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduce the frequency of GVHD by preventive treatment with ECP of patients undergoing allogeneic stem cell transplantation for hematological malignancies GVHD is measured according to internationally recognized criteria up to 1 year after allogeneic stamcell transplantation
Secondary Number of survivors the first year after transplantation In the follow-up periode mortality rate in both groups is registered Through study completion, and until 1 year after study start
Secondary Number of patients who relapsed the first year after transplantation Number of patients who relapsed the first year after transplantation Number of patients who relapsed the first year after transplantation In the follow-up periode relapse rate in both groups is registered Through study completion, and until 1 year after study start
Secondary Quality of life (QoL) the first year after transplantation In the follow-up periode EORTC-QLQ-C30 scores in both groups are registered Through study completion, and until 1 year after study start
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Not yet recruiting NCT00749164 - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment Phase 1/Phase 2
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Active, not recruiting NCT04503616 - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention Phase 1/Phase 2
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Completed NCT00141713 - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Phase 2
Recruiting NCT01991301 - Carfilzomib for the Prevention of Graft Versus Host Disease Phase 1
Completed NCT00408928 - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Phase 2
Completed NCT01633229 - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications Phase 1
Completed NCT05856058 - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability Phase 1
Completed NCT02342613 - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Phase 1
Completed NCT02144025 - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT Phase 2
Completed NCT01369914 - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed NCT00806728 - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease Phase 1
Completed NCT01851382 - Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research